The Drug Controller General of India (DCGI) this week has granted clearance for clinical trials for one more candidate vaccine from India. Genoa company, with the help of the Government of India's research agency Department of Biotechnology, has developed a vaccine, said Dr. Vinod Paul, member of Niti Aayog.

Last week,  Vinod  Paul said that India's drug regulator will grant emergency use licences to covid-19 vaccine candidates under review, after analyzing all aspects of efficacy and safety. Pfizer, Serum Institute of India and Bharat Biotech have applied for market authorization for their vaccines. He further added that the technology used in this is the same as Pfizer vaccine. Unlike the Pfizer vaccine or some others, this vaccine if it comes into existence it will be maintainable at normal cold chain conditions, in a normal fridge.

“We have three applications today for the emergency use authorisation on sound principles. We have Pfizer, we have Bharat Biotech and we have Serum and they have not only met the deadline, they have overtaken the deadline," Paul said.

The Drug Controller General of India (DCGI) this week has granted clearance for clinical trials for one more candidate vaccine from India. Genoa company, with the help of the Government of India's research agency Department of Biotechnology, has developed a vaccine, said Dr. Vinod Paul, member of Niti Aayog.

AstraZeneca removed Children from mid to late stage trials, US Trial Register

EC seeks clarification from Kerala CM on free Covid-19 vaccine statement

Maharastra Govt allots Rs 2211cr for farmers, Rs 22cr for vaccine storage